Literature DB >> 17237273

The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells.

Wendy L Allen1, Estelle G McLean, John Boyer, Andrea McCulla, Peter M Wilson, Vicky Coyle, Daniel B Longley, Robert A Casero, Patrick G Johnston.   

Abstract

Polyamines have been shown to play a role in the growth and survival of several solid tumors, including colorectal cancer. We identified the polyamine catabolic enzyme spermidine/spermine N(1)-acetyltransferase (SSAT) as being one of the most highly inducible genes in two DNA microarray screens to identify novel determinants of response to chemotherapeutic agents in colorectal cancer. SSAT was shown to be inducible in response to 5-fluorouracil (5-FU) or oxaliplatin in parental and drug-resistant HCT116 cell lines. It was also shown that SSAT mRNA was up-regulated in response to 5-FU or oxaliplatin in a panel of six colorectal cancer cell lines. The polyamine analogue N(1),N(11)-diethylnorspermine (DENSpm) depletes polyamine pools and potently induces SSAT. We evaluated the effect of combining DENSpm with chemotherapeutic agents in HCT116 p53(+/+) cells and in HCT116 drug-resistant daughter cell lines. Western blot analyses showed that SSAT protein expression was dramatically enhanced when DENSpm was combined with oxaliplatin or 5-FU in HCT116 p53(+/+) cells. Using cell viability assays and flow cytometry, synergistic induction of cell death was observed following cotreatment of HCT116 p53(+/+) cells with DENSpm and each chemotherapeutic agent. Of note, this combined therapy increased the chemosensitivity of cells rendered resistant to each of these chemotherapeutic agents. Small interfering RNA-mediated down-regulation of SSAT resulted in loss of synergy between DENSpm and these agents. These results show that SSAT plays an important role in regulating cell death following combined cytotoxic drug and DENSpm treatment. Furthermore, DENSpm sensitizes both sensitive and resistant cells to chemotherapeutic agents. Taken together, these results suggest that SSAT may be an important target for therapeutic intervention in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237273     DOI: 10.1158/1535-7163.MCT-06-0303

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  19 in total

1.  Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.

Authors:  Ramakumar Tummala; Paula Diegelman; Suzanne Hector; Debora L Kramer; Kimberly Clark; Patricia Zagst; Gerald Fetterly; Carl W Porter; Lakshmi Pendyala
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-05       Impact factor: 3.333

2.  Identification of hypermethylated genes associated with cisplatin resistance in human cancers.

Authors:  Xiaofei Chang; Constance L Monitto; Semra Demokan; Myoung Sook Kim; Steven S Chang; Xiaoli Zhong; Joseph A Califano; David Sidransky
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

3.  Inhibition of autophagy enhances DENSpm-induced apoptosis in human colon cancer cells in a p53 independent manner.

Authors:  Ajda Coker Gurkan; Elif Damla Arisan; Pinar Obakan Yerlikaya; Halime Ilhan; Narcin Palavan Unsal
Journal:  Cell Oncol (Dordr)       Date:  2018-02-28       Impact factor: 6.730

4.  Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells.

Authors:  Ramakumar Tummala; Paula Diegelman; Sonia M Fiuza; Luis A E Batista de Carvalho; Maria Paula M Marques; Debora L Kramer; Kimberly Clark; Slavoljub Vujcic; Carl W Porter; Lakshmi Pendyala
Journal:  Oncol Rep       Date:  2010-07       Impact factor: 3.906

5.  Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells.

Authors:  Pınar Obakan; Elif Damla Arısan; Pelin Özfiliz; Ajda Çoker-Gürkan; Narçin Palavan-Ünsal
Journal:  Mol Biol Rep       Date:  2013-11-05       Impact factor: 2.316

Review 6.  Polyamine metabolism and cancer: treatments, challenges and opportunities.

Authors:  Robert A Casero; Tracy Murray Stewart; Anthony E Pegg
Journal:  Nat Rev Cancer       Date:  2018-11       Impact factor: 60.716

7.  The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Authors:  Allison Pledgie-Tracy; Madhavi Billam; Amy Hacker; Michele D Sobolewski; Patrick M Woster; Zhe Zhang; Robert A Casero; Nancy E Davidson
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-30       Impact factor: 3.333

8.  Overexpression of SSAT by DENSPM treatment induces cell detachment and apoptosis in glioblastoma.

Authors:  Ye Tian; Shizhao Wang; Bin Wang; Jianning Zhang; Rongcai Jiang; Wei Zhang
Journal:  Oncol Rep       Date:  2011-12-14       Impact factor: 3.906

9.  Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells.

Authors:  A Çoker; E D Arısan; N Palavan-Ünsal
Journal:  Mol Med Rep       Date:  2012-01-30       Impact factor: 2.952

10.  A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.

Authors:  Tracy Murray Stewart; Daniel Von Hoff; Michael Fitzgerald; Laurence J Marton; Carlos H Roberto Becerra; Thomas E Boyd; Paul R Conkling; Lawrence E Garbo; Robert M Jotte; Donald A Richards; David A Smith; Joe J Stephenson; Nicholas J Vogelzang; Hillary H Wu; Robert A Casero
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-19       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.